

## REPLY TO REVIEWERS

Ms No. 64811- Clozapine resistant schizophrenia: newer avenues of management

### Reviewer #1:

**Scientific Quality:** Grade C (Good)

**Language Quality:** Grade A (Priority publishing)

**Conclusion:** Major revision

**Specific Comments to Authors:** The title of the article focuses on the new management strategy of olanzapine resistance. This is a very meaningful clinical topic. However, in addition to clinical resistance, olanzapine has serious side effects, especially on metabolism. Moreover, the incidence and treatment of schizophrenia have certain gender differences. The author should also include in the review whether there are reports on the gender differences in the clinical treatment of olanzapine and what the current situation is. The above two points are suggested to be discussed in detail in the revised manuscript, so as to finish a complete clinical topic.

## REPLY

I expect that the reviewer is referring to clozapine resistance.

About metabolic side effects of clozapine, there are a few lines in the manuscript on page 18 (section on Optimizing clozapine treatment) -

*Many of the common side effects encountered with clozapine including metabolic side effects are dose-dependent [81, 127]. Using the lowest effective dose, slow increase in doses, and dose adjustments to minimize side effects is thus recommended [81, 120, 123].*

I have enlarged this section to add further details on the prevalence, risk factors and management of metabolic syndrome with clozapine on page 20 of the revision.

Details on gender differences in clozapine treatment including differences in treatment-response, pharmacokinetics, and side effects have been added in the same section on pages 18-19 of the revision.

A few lines have been added to provide additional information on ethnic differences on pages 19-21 of the revision.

References have been provided for all these details and the reference list has been enlarged in the revision. All changes have been highlighted.

#### Editorial office's comments

Issues raised: No additional comments.

#### Cover letter

Lian-Sheng Ma,  
Science Editor, Company Editor-in-Chief,  
Editorial Office

**Re:** Revision of MS no 64811- Clozapine resistant schizophrenia: newer avenues of management

Dear Sir,

Thank you for your mail. I also wish to thank the reviewer for his/her comments. I have revised the manuscript according to the comments of the reviewer.

The following files are being uploaded:

- (1) 64811-Answering Reviewers
- (2) 64811- Revised manuscript file (changes have been highlighted)
- (3) 64811-Audio Core Tip
- (4) 64811-Conflict-of-Interest Disclosure Form

- (5) 64811-Copyright License Agreement
- (6) 64811-Non-Native Speakers of English Editing Certificate
- (7) 64811-Table File

The study was not funded. So the approved grant application form(s) or funding agency copy of any approval document(s) are not included. There are no video, image or supplementary files.

I would grateful if the revision is re-evaluated for publication in the World Journal of Psychiatry.

With regards,

Subho Chakrabarti

Professor, Dept of Psychiatry, PGIMER, Chandigarh, India

ID (02445242)